XTL Biopharmaceuticals Moves To Acquire 85% Of NeuroNOS And Has Already Scheduled A Shareholders Meeting For February 17, 2026 To Approve A Private Placement Of Up To $2M
XTL Biopharmaceuticals計劃收購NeuroNOS 85%的股份，並已安排於2026年2月17日召開股東大會，以批准一項最高金額達$200萬的私募配售。
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company's Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million.
XTL Biopharmaceuticals Ltd.（納斯達克：XTLB）（特拉維夫證券交易所：XTLB.TA）（以下簡稱「公司」或「XTL」）宣佈，繼2026年1月13日簽署具有約束力的意向書後（如公司於2026年1月13日提交的《外國私人發行人報告》表格6-K中所披露），公司正在積極努力完成對NeuroNOS Ltd. 85%股權的收購，並已安排在2026年2月17日召開股東大會，以批准一項最高金額爲US$200萬的定向增發。
Management of the Company believes that the completion of the proposed transaction to acquire 85% of the shares of NeuroNOS Ltd...
公司管理層認爲，完成擬議的收購Neuro...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
